Skip to content

Home
About
Investment Strategy
Portfolio
News
Contact

Enveda Biosciences Series B1

April 20, 2023

Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

Investing in exceptional founders building the future.

Home
About
Portfolio
News
Contact

© 2026 AgileAngel. All rights reserved.